Example ImageÃÀ¸ß÷

EN
EN
  • ÓªÒµ×Éѯ

    Öйú£º

    Email: marketing@medicilon.com.cn

    ÓªÒµ×ÉѯרÏߣº400-780-8018

    £¨½öÏÞЧÀÍ×Éѯ£¬£¬ £¬ÆäËûÊÂÒËÇ벦´ò´¨É³×ܲ¿µç»°£©

    ´¨É³×ܲ¿µç»°: +86 (21) 5859-1500

    ÍâÑó£º

    +1(781)535-1428(U.S.)

    0044 7790 816 954 (Europe)

    Email:marketing@medicilon.com

ÔÚÏßÁôÑÔ¡Á
µã»÷Çл»
Customer Center
¿Í»§ÖÐÐÄ

ŵ»ªKisqaliÔÙ»ñFDAÅú×¼£¬£¬ £¬ÖÎÁÆÔçÆÚÈéÏÙ°©

2024-09-18
|
»á¼ûÁ¿£º

΢ÐÅͼƬ_20240914163101.jpg

Ò½ÏßÒ©ÎÅ

1. 9ÔÂ18ÈÕ£¬£¬ £¬Åµ»ª£¨Novartis£©Ðû²¼£¬£¬ £¬ÃÀ¹úFDAÒÑÅú×¼CDK4/6ÒÖÖÆ¼ÁKisqali£¨ribociclib£©ÁªºÏ·¼ÏãøÒÖÖÆ¼Á£¨AI£©£¬£¬ £¬×÷Ϊ¸ß¸´·¢Î£º¦µÄ¼¤ËØÊÜÌåÑôÐÔ/ÈË±íÆ¤Éú³¤Òò×ÓÊÜÌå2ÒõÐÔ£¨HR+/HER2-£©IIÆÚºÍIIIÆÚÔçÆÚÈéÏÙ°©£¨EBC£©»¼Õߵĸ¨ÖúÖÎÁÆ£¬£¬ £¬°üÀ¨ÎÞÁÜͶºÏ×ªÒÆ£¨N0£©µÄ»¼Õß¡£¡£¡£¡£¡£¡£

2. 9ÔÂ18ÈÕ£¬£¬ £¬¾ÝCDE¹ÙÍøÐÂÎÅ£¬£¬ £¬ËÕÖÝÐÅŵάҽҩ¿Æ¼¼¹É·ÝÓÐÏÞ¹«Ë¾ÁªºÏÉêÇëÒ©Æ·¡°×¢ÉäÓÃÑǰ·ÅàÄÏÎ÷˾Ëû¶¡ÄƸ£Åµ°Í̹¡±£¬£¬ £¬»ñµÃÁÙ´²ÊÔÑéĬʾÔÊÐí£¬£¬ £¬Ë³Ó¦Ö¢£º±¾Æ·ÊÊÓÃÓÚ 18 Ëê¼°ÒÔÉϵϼÕߣ¬£¬ £¬ÖÎÁÆÓɶԱ¾Æ·Ãô¸ÐµÄ¸ïÀ¼ÒõÐÔ¾ú£¬£¬ £¬°üÀ¨±«Âü²»¶¯¸Ë¾ú£¬£¬ £¬´ó³¦¸Ë¾ú£¨Èç·ÎÑ׿ËÀײ®¸Ë¾ú£¬£¬ £¬´ó³¦°£Ï£¾ú£©£¬£¬ £¬Í­Â̼ٵ¥°û¾úÒýÆðµÄÒÔÏÂѬȾ£ºÒ½Ôº»ñµÃÐÔϸ¾úÐÔ·ÎÑ׺ͺôÎü»úÏà¹ØÐÔϸ¾úÐÔ·ÎÑ×£¨HABP/VABP£©¡£¡£¡£¡£¡£¡£

3. 9ÔÂ18ÈÕ£¬£¬ £¬¿ÆÂ×Ò©ÒµÐû²¼Í¨¸æ£¬£¬ £¬¹«Ë¾»¯Ñ§Ò©Æ·µØÇüÔÐͪƬÓÚ¿ËÈÕ»ñµÃ¹ú¼ÒÒ©Æ·¼àÊÓ¹ÜÀí¾ÖµÄÒ©Æ·×¢²áÅú×¼¡£¡£¡£¡£¡£¡£µØÇüÔÐͪƬΪÑÅÅ࿪·¢£¬£¬ £¬ÓÃÓÚÖÎÁÆÄÚÔ´ÐÔÔÐͪȱ·¦ÒýÆðµÄÏà¹Ø¼²²¡£¡£¡£¡£¡£¡£¬£¬ £¬ÈçÍ´¾­¡¢×Ó¹¬ÄÚĤÒìλ֢¡¢Ôм¤ËØÈ±·¦ËùÖÂÏÈÕ×ÐÔÁ÷²ú»òϰ¹ßÐÔÁ÷²ú¼°¸¨ÖúÉúÖ³¼¼ÊõÖеĻÆÌåÖ§³ÖµÈ¡£¡£¡£¡£¡£¡£

4. 9ÔÂ18ÈÕ£¬£¬ £¬Ðû̩ҽҩͨ¸æ£¬£¬ £¬¹«Ë¾Ïò¹ú¼ÒÒ©Æ·¼àÊÓ¹ÜÀí¾ÖÉ걨µÄ´ï¸ñÁо»¶þ¼×Ë«ëÒ»ºÊÍÆ¬²úÆ·ÒÑ»ñµÃÕýʽÅú×¼£¬£¬ £¬Îª¸ÃÆ·ÖÖº£ÄÚÊ×¼Ò»ñÅúµÄ·ÂÖÆÒ©¡£¡£¡£¡£¡£¡£´ï¸ñÁо»¶þ¼×Ë«ëÒ»ºÊÍÆ¬ÓÃÓÚÖÎÁÆ2ÐÍÌÇÄò²¡¡£¡£¡£¡£¡£¡£

ͶÈÚÒ©ÊÂ

1. 9ÔÂ17ÈÕ£¬£¬ £¬Ò»¼Ò¿ª·¢ÓÃÓÚÖÎÁÆÓÐÊý¼²²¡µÄת»¯Ï¸°ûºÍÍâÃÚÌåÁÆ·¨µÄÉúÎï¼¼Êõ¹«Ë¾Capricor Therapeutics Ðû²¼ÒÑÓëÈÕ±¾ÐÂÒ©Öêʽ»áÉç¾ÍÇ©ÊðÁ˾ßÓÐÔ¼ÊøÁ¦µÄÌõ¿îÇåµ¥¡£¡£¡£¡£¡£¡£Ìõ¿îÌåÏÖ£¬£¬ £¬ÈÕ±¾ÐÂÒ©Öêʽ»áÉ罫ÔÚÅ·ÖÞÉÌÒµ»¯ºÍ·ÖÏú Capricor µÄÖ÷Òª×ʲú deramiocel£¬£¬ £¬ÓÃÓÚÖÎÁƶÅÊϼ¡ÓªÑø²»Á¼Ö¢ (DMD)¡£¡£¡£¡£¡£¡£Capricor ½«ÒÔ 20% µÄÒç¼Û»ñµÃ 1500 ÍòÃÀÔªµÄ¹ÉȨͶ×Ê£¬£¬ £¬²¢ÔÚÇ©Êð×îÖÕЭÒéºó»ñµÃ 2000 ÍòÃÀÔªµÄÔ¤¸¶¿î£¬£¬ £¬ÆäÖÐDZÔÚÀï³Ì±®½ð¶î¸ß´ï 7.15 ÒÚÃÀÔª£¬£¬ £¬²úÆ·ÊÕÈëÕ¼±ÈµÖ´ïÁ½Î»Êý£¬£¬ £¬×ۺϷÖÏúЭÒéµÄDZÔÚÀï³Ì±®ÏÖÔÚ×ܶîԼΪ 15 ÒÚÃÀÔª¡£¡£¡£¡£¡£¡£

¿Æ¼¼Ò©ÑÐ

1. ¿ËÈÕ£¬£¬ £¬À´×ÔÓ¢¹ú½£ÇÅ´óѧµÄMasashi NaritaÍŶÓÓÚNatureÉÏÔÚÏß½ÒÏþÌâΪTitration of RAS alters senescent state and influences tumour initiationµÄÎÄÕ£¬£¬ £¬Í¨¹ýÌåÍâºÍÌåÄÚÄ£×Ó£¬£¬ £¬Õ¹ÏÖÁËRAS»ùÒò¼ÁÁ¿µÝÔö¶ÔÖ×ÁöÉú³¤µÄÓ°Ï죬£¬ £¬·¢Ã÷NRAS (G12V)±í ´ïˮƽÓë¸Îϸ°ûOIS±íÐͺÍÖ×ÁöÃâÒßɨ³ýÓйأ¬£¬ £¬Ö¤Êµ²î±ðNRAS (G12V) ˮƽµ¼Ö²î±ðÖ×ÁöÀàÐÍ£¬£¬ £¬ÓëÈËÀà¸Îϸ°û°©£¨HCC£©ÑÇÀàÏà¹Ø£¬£¬ £¬ÖØÐ½ç˵ÁËÓÉÖ°©¼ÁÁ¿Çý¶¯µÄOISÆ×ϵ£¬£¬ £¬Ð­µ÷ÁËÔçÆÚÖ×Áö±¬·¢ÖеÄÐàÂõºÍÖ×Áö±¬·¢±íÐÍ¡£¡£¡£¡£¡£¡£

[1] Chan, A.S.L., Zhu, H., Narita, M. et al. Titration of RAS alters senescent state and influences tumour initiation. Nature (2024). https://doi.org/10.1038/s41586-024-07797-z

Ïà¹ØÐÂÎÅ
¡Á
ËÑË÷ÑéÖ¤
µã»÷Çл»
¡¾ÍøÕ¾µØÍ¼¡¿¡¾sitemap¡¿